Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 79,259 Shares of Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc purchased 79,259 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $13.99 per share, with a total value of $1,108,833.41. Following the acquisition, the insider directly owned 909,843 shares in the company, valued at $12,728,703.57. This represents a 9.54% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Friday, May 15th, Adar1 Capital Management, Llc purchased 300 shares of Rallybio stock. The shares were purchased at an average price of $13.90 per share, with a total value of $4,170.00.
• On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The shares were purchased at an average price of $13.83 per share, with a total value of $11,064.00.
• On Monday, May 11th, Adar1 Capital Management, Llc bought 50,000 shares of Rallybio stock. The stock was bought at an average price of $14.00 per share, with a total value of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc bought 35,101 shares of Rallybio stock. The stock was bought at an average price of $14.00 per share, with a total value of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc bought 120,804 shares of Rallybio stock. The stock was bought at an average price of $13.97 per share, with a total value of $1,687,631.88.

Rallybio Stock Performance

Shares of Rallybio stock opened at $14.30 on Friday. The stock has a market cap of $75.65 million, a price-to-earnings ratio of -3.14 and a beta of -1.10. The stock has a 50 day moving average price of $9.84 and a 200-day moving average price of $7.05. Rallybio Corporation has a one year low of $2.16 and a one year high of $15.31.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%. The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million.

Analyst Ratings Changes

RLYB has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a research note on Friday, May 8th. Wall Street Zen raised Rallybio to a “hold” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. XTX Topco Ltd increased its holdings in shares of Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares during the period. Geode Capital Management LLC increased its holdings in shares of Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares during the period. Susquehanna International Group LLP increased its holdings in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares during the period. Finally, Citadel Advisors LLC increased its holdings in shares of Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares during the period. 90.34% of the stock is owned by institutional investors and hedge funds.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.